AIC
PVLA

Archer Investment Corporation’s Palvella Therapeutics PVLA Stock Holding History

Archer Investment Corporation’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$68.6K Hold
449
– – 0.01% 483
2026
Q1 		$56K Hold
449
– – 0.01% 510
2025
Q4 		$47K Hold
449
– – 0.01% 481
2025
Q3 		$28.1K Buy
+449
New +$20K 0.01% 566

Other funds holding PVLA

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
CAM
Clio Asset Management Charlottesville, Virginia $126M AUM 16.01% 1-Year Est. Return

Archer Investment Corporation's PVLA Position: Q2 2026 in Review

Archer Investment Corporation held its Palvella Therapeutics (PVLA) position steady in Q2 2026 at 449 shares worth $68.6K. The position accounts for 0.01% of the portfolio, ranked #483.

Archer Investment Corporation first reported a position in PVLA in Q3 2025 and has held it in 4 quarters since. 107 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • Archer Investment Corporation held 449 shares of Palvella Therapeutics worth $68.6K as of Q2 2026.
  • Archer Investment Corporation left its Palvella Therapeutics share count unchanged in Q2 2026.
  • Palvella Therapeutics made up 0.01% of Archer Investment Corporation's portfolio in Q2 2026, its #483 holding.
  • Archer Investment Corporation first reported a position in Palvella Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 107 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Archer Investment Corporation's 13F filing for Q2 2026, filed 3 Aug 2026.